US · Healthcare · Biotechnology
EPS came in at -0.13 against a street estimate of -0.16 — a beat of 18.8%.
Analysts rate Allogene Therapeutics Inc a buy (12 buy, 2 hold, 0 sell out of 14) with an average price target of $9.00.
| Fund | Stake |
|---|---|
| Pfizer Inc | 6.38% |
| BlackRock Inc | 5.53% |
| TPG GP A, LLC | 5.42% |
| Sio Capital Management, LLC | 3.86% |
| PRIMECAP Management Company | 3.80% |
| Citadel Advisors Llc | 2.92% |
| State Street Corp | 2.51% |
| Two Sigma Investments LLC | 2.25% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 ALLOGENE THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Filing Date: September 2, 2026 • Report Date: August 31, 2026 • Company: Allogene Thera | 2026-09-02 |
| Quarterly report · Q2 2026 ALLOGENE THERAPEUTICS, INC. — FORM 10-Q SUMMARY (Q2 2026) --- HEADLINE NUMBERS • Cash & Investments Position (June 30, 2026): $423.6 million total | 2026-08-12 |
| Results announced · Q3 2026 ALLOGENE THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $423.6 million in cash, cash equivalents, and investments | 2026-08-12 |
| Shareholder vote results · Q2 2026 ALLOGENE THERAPEUTICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • As of April 20, 2026 (record date), 345,024,351 shares of common stock were outsta | 2026-06-22 |
| Board / officer change · Q2 2026 ALLOGENE THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • New CEO appointment effective July 1, 2026: Zachary Roberts, M.D., Ph.D. replacing Davi | 2026-05-28 |
| Quarterly report · Q1 2026 ALLOGENE THERAPEUTICS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and investments: $266.9 million as of March 31, 2026 (cash $30.3M, short- | 2026-05-13 |
| Proxy statement · Q2 2026 ALLOGENE THERAPEUTICS, INC. — 2026 PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect three board nominees to serve until the 2029 An | 2026-04-30 |
| Annual report FY2025 ALLOGENE THERAPEUTICS, INC. – 10-K SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Stock Price & Market Cap: As of June 30, 2025, aggregate mar | 2026-03-12 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Allogene Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.